|
gptkbp:instanceOf
|
gptkb:receptor_tyrosine_kinase
gptkb:drug
EGFR inhibitor
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2015
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01EB04
|
|
gptkbp:brand
|
gptkb:Tagrisso
|
|
gptkbp:CASNumber
|
1421373-65-0
|
|
gptkbp:chemicalFormula
|
C28H33N7O2
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
|
|
gptkbp:eliminatedIn
|
urine
feces
|
|
gptkbp:halfLife
|
48 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Osimertinib
|
|
gptkbp:indication
|
metastatic EGFR T790M mutation-positive NSCLC
|
|
gptkbp:KEGGID
|
D10568
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
irreversible EGFR inhibitor
|
|
gptkbp:metabolism
|
gptkb:CYP3A5
gptkb:CYP3A4
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
gptkb:DB09330
CHEMBL3185146
71512363
|
|
gptkbp:sideEffect
|
nausea
diarrhea
rash
interstitial lung disease
|
|
gptkbp:synonym
|
gptkb:Tagrisso
gptkb:AZD9291
|
|
gptkbp:target
|
gptkb:EGFR_T790M_mutation
gptkb:epidermal_growth_factor_receptor
|
|
gptkbp:UNII
|
7A5O2R1WUF
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
|
|
gptkbp:bfsParent
|
gptkb:Non-Small_Cell_Lung_Cancer
gptkb:162359-55-9
|
|
gptkbp:bfsLayer
|
6
|